Literature DB >> 27730530

A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity.

Tomoko Matsumoto1,2, Keiji Nogami3, Midori Shima1,2.   

Abstract

Patients with mild/moderate hemophilia (H)A, acquired HA (AHA) and lupus anticoagulants (LA), have prolonged aPTTs with low levels of factor (F)VIII activity, but the differentiation of these disorders is complex and time consuming. We established an approach to quickly differentiate these disorders using comprehensive coagulation tests. Patients' plasmas with mild/moderate HA, AHA, LA without anti-phospholipid syndrome [LA-APS(-)], and LA with APS [LA-APS(+)] were examined using clot waveform analysis (CWA) and thrombin generation test (TGT). Activated protein C (APC) sensitivity was assessed by TGT. CWA revealed similarly prolonged clot times in all groups [NP/mild/moderate HA/AHA/LA-APS(-)/LA-APS(+); 33 ± 1/82 ± 12/116 ± 44/90 ± 29/96 ± 15 s] but significantly different decreased maximal coagulation velocity (3.1 ± 0.1/1.3 ± 0.3/0.9 ± 0.5/1.6 ± 0.3/2.2 ± 0.5). In TGT, AHA group demonstrated severely reduced peak-thrombin levels (362 ± 23/170 ± 27/49 ± 21/158 ± 75/158 ± 99 nM), whilst both LA groups markedly prolonged lag times (4.5 ± 0.3/5.0 ± 0.4/4.7 ± 0.8/12.5 ± 7.7/28.8 ± 11.8 min), suggesting that AHA could be readily identified, but the different LA sub-types failed to be classified. An APC sensitivity demonstrated that 'normalized' APC-induced levels of peak thrombin in LA-APS(+) were significantly lower relative to LA-APS(-) (normalized %inhibition; 5 ± 7/42 ± 39 %). Our studies confirmed that %inhibition by APC was significantly decreased in NP preincubated with purified IgGs from LA-APS(+) compared to LA-APS(-), facilitating differentiation between LA groups. A combined approach using CWA and TGT could be a useful means of differentiating coagulation disorders with prolonged aPTT.

Entities:  

Keywords:  Clot waveform analysis; FVIII inhibitors; Hemophilia A; Lupus anticoagulants; Thrombin generation test

Mesh:

Substances:

Year:  2016        PMID: 27730530     DOI: 10.1007/s12185-016-2108-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  22 in total

1.  Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.

Authors:  G C White; F Rosendaal; L M Aledort; J M Lusher; C Rothschild; J Ingerslev
Journal:  Thromb Haemost       Date:  2001-03       Impact factor: 5.249

Review 2.  Prolonged Activated Partial Thromboplastin Time: Difficulties in Discriminating Coexistent Factor VIII Inhibitor and Lupus Anticoagulant.

Authors:  Paul R J Ames; Maria Graf; Jeremy Archer; Nicola Scarpato; Luigi Iannaccone
Journal:  Clin Appl Thromb Hemost       Date:  2014-07-02       Impact factor: 2.389

3.  The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C).

Authors:  Midori Shima; Tomoko Matsumoto; Kazuyoshi Fukuda; Youko Kubota; Ichiro Tanaka; Katumi Nishiya; Alan R Giles; Akira Yoshioka
Journal:  Thromb Haemost       Date:  2002-03       Impact factor: 5.249

4.  A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies.

Authors:  Tomoko Matsumoto; Keiji Nogami; Kenichi Ogiwara; Midori Shima
Journal:  Thromb Haemost       Date:  2012-01-11       Impact factor: 5.249

5.  Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants.

Authors:  Katrien Devreese; Kathelijne Peerlinck; Marc F Hoylaerts
Journal:  Blood       Date:  2009-11-25       Impact factor: 22.113

6.  Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants.

Authors:  S Liestøl; P M Sandset; M-C Mowinckel; F Wisløff
Journal:  J Thromb Haemost       Date:  2007-11       Impact factor: 5.824

7.  A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A.

Authors:  Tomoko Matsumoto; Keiji Nogami; Kenichi Ogiwara; Midori Shima
Journal:  Int J Hematol       Date:  2009-11-25       Impact factor: 2.490

Review 8.  Standardization and clinical utility of thrombin-generation assays.

Authors:  Erik Berntorp; Gian Luca Salvagno
Journal:  Semin Thromb Hemost       Date:  2008-12-15       Impact factor: 4.180

9.  Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus.

Authors:  Junzo Nojima; Yoshinori Iwatani; Kiyoshi Ichihara; Hidehiro Tsuneoka; Toshizo Ishikawa; Masashi Yanagihara; Toru Takano; Yoh Hidaka
Journal:  Thromb Res       Date:  2009-01-07       Impact factor: 3.944

10.  Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference.

Authors:  M Okuda; Y Yamamoto
Journal:  Clin Lab Haematol       Date:  2004-06
View more
  6 in total

1.  Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis.

Authors:  Konami Kato; Yuki Hatayama; Hisashi Shimohiro; Hitomi Ichikawa; Tetsuya Fukuda
Journal:  Yonago Acta Med       Date:  2022-08-29       Impact factor: 1.371

2.  Acquired hemophilia A associated with autoimmune pancreatitis with serum IgG4 elevation.

Authors:  Taisuke Narazaki; Shojiro Haji; Yasuhiro Nakashima; Yasuhiro Tsukamoto; Mariko Tsuda; Akiko Takamatsu; Hirofumi Ohno; Takamitsu Matsushima; Tomoko Matsumoto; Keiji Nogami; Midori Shima; Motoaki Shiratsuchi; Yoshihiro Ogawa
Journal:  Int J Hematol       Date:  2018-03-26       Impact factor: 2.490

3.  An Evaluation of the Activated Partial Thromboplastin Time Waveform.

Authors:  Takeshi Matsumoto; Hideo Wada; Naoki Fujimoto; Junki Toyoda; Yasunori Abe; Kohshi Ohishi; Yoshiki Yamashita; Makoto Ikejiri; Kei Hasegawa; Kei Suzuki; Hiroshi Imai; Kaname Nakatani; Naoyuki Katayama
Journal:  Clin Appl Thromb Hemost       Date:  2017-09-08       Impact factor: 2.389

4.  Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk.

Authors:  Kei Suzuki; Hideo Wada; Takeshi Matsumoto; Makoto Ikejiri; Kohshi Ohishi; Yoshiki Yamashita; Hiroshi Imai; Toshiaki Iba; Naoyuki Katayama
Journal:  Thromb J       Date:  2019-06-28

5.  Update on the Clot Waveform Analysis.

Authors:  Hideo Wada; Takeshi Matsumoto; Kohshi Ohishi; Katsuya Shiraki; Motomu Shimaoka
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

6.  Clot Waveform Analysis Demonstrates Low Blood Coagulation Ability in Patients with Idiopathic Thrombocytopenic Purpura.

Authors:  Hideo Wada; Yuhuko Ichikawa; Minoru Ezaki; Katsuya Shiraki; Isao Moritani; Yoshiki Yamashita; Takeshi Matsumoto; Masahiro Masuya; Isao Tawara; Hideto Shimpo; Motomu Shimaoka
Journal:  J Clin Med       Date:  2021-12-20       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.